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Advances in mechanical circulatory support have signifi-
cantly expanded the treatment options for patients with 
heart failure, whether acute or chronic. There are numer-
ous devices available that offer patients short-, interme-
diate-, and long-term duration of support depending on 
their clinical needs and cardiac recovery. Each device has 
its own technical considerations and the decision which 
device to use depends on several factors, including what 
is available, the degree of support required, and expect-
ed duration of support. Additional issues that need to 
be considered in choosing level of support include right 
heart function, respiratory failure, and multi-organ de-
rangements. A widespread availability of short-term ven-
tricular assist devices and timely institution for effective 
hemodynamic support will translate into improved patient 
outcomes whether that is successful transfer to a tertiary 
care facility or recovery of inherent cardiac function. Im-
plantable ventricular assist devices have and will continue 
to evolve into smaller and more durable devices, and the 
future for patients with advanced heart failure looks ever-
more promising.
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The limited efficacy of medical therapy to treat end-stage 
heart failure (ESHF), shortage of available donor hearts, and 
the increasing number of patients who do not qualify for 
transplant candidacy despite worsening heart failure have 
all fueled the evolution of mechanical circulatory support. 
Currently, long-term implantable left ventricular assist de-
vices (LVAD) have significantly expanded treatment op-
tions for patients with ESHF as a bridge-to-decision, recov-
ery, transplant, or destination therapy (DT) (1). Mirroring 
the progress and success of long-term LVADs, advances 
have similarly been made in the use of short-term VADs for 
the treatment of cardiogenic shock, whether in the cardiac 
catheterization laboratory or the post-cardiotomy setting 
(2). However, despite improving technology, there is still 
a growing need for wider application of these short-term 
devices, especially in non-tertiary care centers where lack 
of access to this technology results in delayed referral and 
transport to advanced centers and potentially compromis-
es patient outcome. In this setting, there is still a question 
as to the ideal support device, duration of support, and 
timing to bridge these critical patients to a longer-term 
device. Device selection in these circumstances depends 
on several factors, including the degree of support that is 
required acutely, logistical/technical considerations, con-
comitant issues besides left ventricular dysfunction (es-
pecially right ventricular or pulmonary dysfunction), and 
what is available. We review current devices approved by 
the Food and Drug Administration for short-, intermediate-, 
and longer-term support, as well as examine the critical is-
sues to be considered with selecting a device. These in-
clude timing of support, varying technical specifics of each 
device, and expected duration of support. In addition, we 
provide the advantages and disadvantages of each device 
and provide an algorithm for decision-making and device 
selection in these patients.
CardiogeniC ShoCk and Short-terM deviCeS
The immediate goal for patients in cardiogenic shock is 
the re-establishment of normal hemodynamics and re-
storing vital organ perfusion. Cardiogenic shock can occur 
as a result of myocardial ischemia, valvular heart disease, 
myocardial disorders (ie, myocarditis), or mechanical com-
plications of myocardial infarction. Ideally, left ventricular 
support in this setting should be easy to institute, able to 
rapidly stabilize the patient, able to be transported with 
the patient, and allow adequate duration of support to ad-
dress organ derangements and evaluation of neurologic 
status. A common approach in these patients is conserva-
tive, stepwise escalation of support before committing the 
patient to a more effective mechanical circulatory support 
(MCS), ie, maximal inotropes, followed by intra-aortic bal-
loon pump, then followed by consideration of VAD thera-
py. This approach arguably poses a significant delay in re-
versing malperfusion in these critically ill patients.
Percutaneously implanted devices include the Impella 2.5 
and 5.0 (Abiomed Inc., Danvers, MA, USA), TandemHeart 
(Cardiac Assist, Inc., Pittsburgh, PA, USA), and extracorpo-
real membrane oxygenation (ECMO). The Impella, a micro-
axial flow pump, is inserted through a 13-French catheter 
in the femoral artery and placed across the aortic valve. The 
Impella 2.5 has been successfully used for left ventricular 
support during high-risk coronary intervention and for pa-
tients with myocardial infarction and cardiogenic shock 
(1). The Impella 5.0 can be placed percutaneously or, more 
commonly, through a cutdown for femoral artery access; 
this device received FDA approval in 2009. Both Impella 
devices (2.5 and 5.0) provide direct left ventricular unload-
ing with either 2.5 or 5.0 L/min of flow, respectively. Disad-
vantages of the Impella device include limited availability, 
relatively short duration of support, frequent cannula dis-
lodgement, lower extremity ischemia, and difficulty during 
transport to a tertiary care center (1,2).
The TandemHeart is another percutaneously placed VAD. 
The inflow cannula (17 French) is placed into the femoral 
vein and advanced into the left atrium under fluoroscopic 
guidance by a transseptal puncture. The outflow cannula 
(15 of 17 French) is inserted into the femoral artery. This 
pump has been successfully used for high-risk coronary in-
tervention, post-cardiotomy heart failure, bridge-to-bridge 
(BTB), and bridge-to-transplant (BTT) (1-3). A major disad-
vantage characteristic to this pump includes cannula mi-
gration into the right atrium with resultant profound arteri-
al oxygen desaturation. This device is more easily managed 
during patient transport.
There is considerable experience with ECMO utilized for 
the treatment of cardiogenic shock. The major addition to 
the ECMO circuit is an oxygenator and it is the device of 
choice when patients have both cardiac and respiratory 
failure. Cannulation depends on the clinical situation; cen-
tral cannulation is used in the post-cardiotomy setting and 
percutaneous cannulation through the femoral, subclavi-
an, or neck vessels is more commonly used for cardiogenic 
shock. ECMO can provide full cardiopulmonary support, 
but disadvantages of this device strategy include bleed-
ing because of the strict need for intense anticoagula-
tion, limb ischemia when peripheral cannulation is 
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employed, incomplete left ventricular decompression, and 
difficulty during patient transportation if the circuit is not 
compact and simplified. This type of support can be used 
as bridge-to-recovery (BTR), BTB, or BTT.
interMediate- to Longer-terM deviCeS
The Biomedicus Bio-pump (Medtronic, Inc., Eden Prairie, 
MN, USA) is a centrifugal pump that has been in use since 
the 1980s. One major advantage of this pump is its wide-
spread availability in most centers that perform cardiac 
surgery. It is easy to implant and transport patients on this 
system. However, this pump is prone to fibrin formation 
in the circuit, and other types of circulatory devices have 
emerged.
The Abiomed BVS5000 is a pneumatically-driven assist de-
vice which consists of a filling chamber (fills passively) and 
blood returns to the patient via a pumping chamber. Pul-
satile flow is not usually in concert with native cardiac con-
traction and can produce flows up to 6 L/min. The pump 
head requires exchange every week even with adequate 
anticoagulation. This device can similarly be used as sup-
port until weaning, and as a bridge to longer-term im-
plantable VAD, or BTT.
A newer external VADs based on improved centrifugal 
technology is the CentriMag (Levitronix, Waltham, MA, 
USA). Patients with CentriMag can be supported until 
weaning, as a bridge to a longer-term implantable VAD, 
or transplant (1). Anticoagulation is required, and if fibrin 
deposits form in the circuit or pump head, the pump can 
be exchanged. Each of the devices mentioned above can 
be used for single or biventricular support. The centrifugal 
pumps could be combined with a membrane oxygenator 
to provide effective cardiopulmonary support as an ECMO 
circuit, albeit limited in duration.
Long-terM iMpLantabLe deviCeS
As previously discussed, LVAD selection mainly depends 
on the indication for mechanical circulatory support. In 
the United States, long-term, implantable ventricular assist 
devices have been approved for clinical use on two indica-
tions, either as BTT or DT. This section focuses on long-term 
implantable devices, which have received FDA approval 
for these clinical scenarios.
The clinical indications for use of implantable ventricu-
lar assist devices as BTT mainly parallel the eligibility 
criteria for cardiac transplantation, but its primary thera-
peutic aim is reducing transplant wait list mortality. Various 
VADs based on pulsatile pump technology were approved 
for BTT; these included both paracorporeal pumps such as 
the Thoratec PVAD (Thoratec Inc., Pleasanton, CA, USA) and 
the Berlin Heart Excor (Berlin Heart AG, Berlin, Germany), 
and implantable devices such as the HeartMate XVE and 
Novacor VAD (WorldHeart Inc., Oakland, CA, USA). More re-
cently, The HeartMate II, an axial flow pump, has proven 
to be effective in improving functional status, quality of 
life, and survival in those who clinically deteriorated while 
awaiting transplantation (4). The third generation centrif-
ugal flow pump technology currently utilized in clinical 
practice is the HeartWare HVAD, which is FDA-approved 
for BTT and is under study protocol for DT.
On the other hand, the majority of patients with advanced 
ESHF simply do not become eligible for heart transplanta-
tion due to the limited number of suitable donor hearts. The 
HeartMate XVE was the first device FDA approved based 
largely on the results of the REMATCH trial in which trans-
plant-ineligible patients were randomized to either optimal 
medical management or LVAD therapy (5). At 1 and 2 years, 
there was a highly significant survival benefit for patients 
receiving LVAD therapy compared to optimal medical man-
agement. Also the quality of life was significantly improved 
in those supported on LVADs. Despite gaining FDA approv-
al, widespread implantation did not occur because of its 
large size, specialized patient care requirements, and nu-
merous technical issues. Sepsis and LVAD device failure ac-
counted for the majority of deaths, and high LVAD failure 
rates remained problematic within 2 years (6). Commonly 
accepted indications (Centers for Medicare and Medicaid 
Services criteria) include an ejection fraction <25%, peak 
oxygen consumption of <14 mL/kg/min, New York Heart 
Functional Class IIIB or IV, or dependence on either intra-
aortic balloon or inotrope therapy. Most patients simulta-
neously undergo heart transplant evaluation prior to LVAD 
implantation and based on preoperative testing, they are 
labeled as either BTT or DT. In some instances, transplant 
candidacy is unclear and these patients informally receive 
LVAD therapy as a “bridge to decision.”
LVAD technology has evolved from large, pulsatile pumps 
into smaller, continuous-flow pumps. The HeartMate 2 has 
proven to be significantly more durable than the Heart-
Mate XVE, and survival and quality of life were significantly 
improved in those supported on the new axial flow pumps 
(7). Currently the HeartMate 2 is the only device that is FDA 
approved for both BTT and DT, while the HeartWare HVAD 
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is approved for BTT with the DT trial ongoing. Long-term 
consequences of supporting patients with these continu-
ous flow pumps are yet to be fully understood. Yet, there 
appears to be an increased incidence of bleeding, perhaps 
contributed by anticoagulation, acquired von Willebrand 
deficiency, and/or reduced pulse pressures.
A unique device, which is also FDA approved for BTT, is 
the pneumatic total artificial heart Cardiowest TAH (Syn-
Cardia Systems Inc., Tucson, TX, USA). Indications for TAH 
implantation differ from those of most VADs. This pump is 
mainly for patients with severe cardiogenic shock result-
ing in profound multiple organ derangements, extensive 
myocardial infarction resulting in biventricular failure, left 
ventricular failure with extensive intraventricular thrombi, 
or select cases of primary graft failure or rejection follow-
ing transplantation.
aLgorithM
As discussed earlier, these implantable devices, which are 
currently FDA approved for long-term VAD support for 
either BTT or DT, are typically implanted in patients with 
chronic heart failure after a thorough evaluation process. 
However, in patients that are transferred on the aforemen-
tioned temporary support instituted for cardiogenic shock 
or post cardiac surgery, the evaluation process is quite dif-
ferent and their treatment pathway is dependent on sev-
eral factors (1). Upon arrival, assessment is made of end-
organ function, nutritional support is begun, sedation 
is weaned and thorough echocardiographic evaluation 
is undertaken. If there is recovery of end-organ function, 
neurological status and cardiac function, then temporary 
support can be weaned. If there is end-organ recovery and 
improvement in neurologic status, but cardiac dysfunc-
tion persists, these patients are candidates for HeartMate 
II implantation. In patients that fail to recover end-organ 
function with or without cardiac recovery and have poor 
neurological prognosis, multidisciplinary consideration of 
temporary VAD support withdrawal is undertaken (1).
Patient presentation and acuity of illness dictate the appro-
priateness of which device is selected for support. Tempo-
rary devices can serve as a bridge in order to stabilize pa-
tients and facilitate a work-up for candidacy for long-term 
implantable devices. This field continues to evolve as do 
the indications for their use
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